Krystexxa (pegloticase) is an enzyme made to specifically target uric acid in the treatment of chronic gout. Krystexxa is used for patients that have failed to have success with other treatments.  

Uric acid is created when the body breaks down purines, a chemical compound that cells use to make DNA and RNA. Purines can also be ingested as they are found in high purine foods such as some seafood, meats, alcohol, and sweet drinks.  

In normal amounts, uric acid is passed through the urinary tract to exit the body. When the kidneys are unable to remove enough excess uric acid from the bloodstream, it results in hyperuricemia. The uric acid clumps together forming crystals. These crystals prefer to accumulate in joints, especially in the hands and feet, a condition  known as gout.  

Krystexxa is given to treat severe, treatment-refractory, chronic gout because the enzyme converts uric acid into allantoin, a water-soluble substance the body can easily excrete. This process decreases uric acid levels in the blood, and over time Krystexxa dissolves uric acid crystal buildup, relieving gout symptoms and flares.